IDSA 指南:COVID-19 分子诊断检测
IDSA 多学科专家组采用 GRADE 方法,针对 SARS-CoV-2 核酸检测的使用制定循证诊断指南,共达成 17 条诊断推荐。指南推荐对所有疑似 COVID-19 的症状个体进行核酸检测,有已知或疑似接触史的无症状个体也应检测;无已知暴露的无症状个体,在结果将影响隔离/检疫/PPE 使用、手术资格或移植时机时建议检测。
要点
- 所有疑似 COVID-19 的症状个体均推荐核酸检测。
- 有已知或疑似接触史的无症状个体推荐核酸检测。
- 无暴露的无症状者仅在结果影响隔离、手术或移植决策时建议检测。
核心结论
- IDSA 专家组认为,普遍获得准确的 SARS-CoV-2 核酸检测对患者诊疗、医院感染防控和公共卫生应对至关重要。
- 专家组共达成 17 条诊断推荐,推荐对所有疑似 COVID-19 的症状个体进行核酸检测。
- 有已知或疑似接触 COVID-19 病例的无症状个体也推荐检测。
- 无已知暴露的无症状个体,当结果将影响隔离/检疫/PPE 使用、手术资格或实体器官/造血干细胞移植时机时建议检测。
- 检测优先级最终取决于机构资源和不同患者群体的需求。
研究设计与样本
- IDSA 召集感染病临床医生、临床微生物学家和系统文献综述专家组成多学科专家组。
- 专家组确定并优先排序与 SARS-CoV-2 分子诊断相关的临床问题和结局。
- 采用 GRADE 方法评估证据确定性并制定检测推荐。
- 本文为 IDSA 关于 COVID-19 分子诊断检测的指南。
主要发现
- 专家组就 17 条诊断推荐达成一致。
- 当前文献证据质量被评价为中等至极低。
- 可及检测的临床性能信息正在快速涌现。
关键数值与推荐
- 推荐对所有疑似 COVID-19 的症状个体进行核酸检测。
- 推荐对有已知或疑似接触 COVID-19 病例的无症状个体进行检测。
- 无已知暴露的无症状个体,在结果将影响隔离/检疫/PPE 使用决策、手术资格或实体器官/造血干细胞移植时机时建议检测。
临床怎么用
- 临床遇到疑似 COVID-19 症状患者时,应优先安排 SARS-CoV-2 核酸检测。
- 对明确接触史的无症状者应主动检测,以支持隔离和院感防控决策。
- 无暴露无症状者的检测应结合隔离/PPE、手术安排和移植时机等实际影响来决策。
- 检测策略需结合本机构资源和患者群体需求进行优先级安排。
局限性
- 当前文献证据质量被评价为中等至极低。
- 可及检测的临床性能证据仍在快速变化。
- 检测优先级受机构资源差异影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Accurate molecular diagnostic tests are necessary for confirming a diagnosis of coronavirus disease 2019 (COVID-19). Direct detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acids in respiratory tract specimens informs patient, healthcare institution and public health level decision-making. The numbers of available SARS-CoV-2 nucleic acid detection tests are rapidly increasing, as is the COVID-19 diagnostic literature. Thus, the Infectious Diseases Society of America (IDSA) recognized a significant need for frequently updated systematic reviews of the literature to inform evidence-based best practice guidance. OBJECTIVE: The IDSA's goal was to develop an evidence-based diagnostic guideline to assist clinicians, clinical laboratorians, patients and policymakers in decisions related to the optimal use of SARS-CoV-2 nucleic acid amplification tests. In addition, we provide a conceptual framework for understanding molecular diagnostic test performance, discuss the nuance of test result interpretation in a variety of practice settings and highlight important unmet research needs in the COVID-19 diagnostic testing space. METHODS: IDSA convened a multidisciplinary panel of infectious diseases clinicians, clinical microbiologists, and experts in systematic literature review to identify and prioritize clinical questions and outcomes related to the use of SARS-CoV-2 molecular diagnostics. Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess the certainty of evidence and make testing recommendations. RESULTS: The panel agreed on 17 diagnostic recommendations. CONCLUSIONS: Universal access to accurate SARS-CoV-2 nucleic acid testing is critical for patient care, hospital infection prevention and the public response to the COVID-19 pandemic. Information on the clinical performance of available tests is rapidly emerging, but the quality of evidence of the current literature is considered moderate to very low. Recognizing these limitations, the IDSA panel weighed available diagnostic evidence and recommends nucleic acid testing for all symptomatic individuals suspected of having COVID-19. In addition, testing is recommended for asymptomatic individuals with known or suspected contact with a COVID-19 case. Testing asymptomatic individuals without known exposure is suggested when the results will impact isolation/quarantine/personal protective equipment (PPE) usage decisions, dictate eligibility for surgery, or inform solid organ or hematopoietic stem cell transplantation timing. Ultimately, prioritization of testing will depend on institutional-specific resources and the needs of different patient populations.
引用
- Hanson KE, Caliendo AM, Arias CA, et al. The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing. Clin Infect Dis. 2021. PMID: 33480973. doi:10.1093/cid/ciab048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。